

Chapter Phar 1

AUTHORITY AND DEFINITIONS

Phar 1.01 Authority.

Phar 1.02 Definitions.

Note: Chapter Phar 1 as it existed on January 31, 1983 was repealed and a new chapter Phar 1 was created effective February 1, 1983.

Phar 1.01 Authority. Rules in chs. [Phar 1](#) to [19](#) are adopted under authority of ss. [15.08 \(5\) \(b\)](#) and [227.11 \(2\)](#), Stats., and ch. [450](#), Stats.

History: Cr. [Register, January, 1983, No. 325](#), eff. 2-1-83; am. [Register, August, 1991, No. 428](#), eff. 9-1-91; am., [Register, December, 1998, No. 516](#), eff. 1-1-99; am., [Register, March, 2000, No. 531](#), eff. 4-1-00; correction made under s. 13.93 (2m) (b) 7., Stats., [Register January 2002 No. 553](#); CR 17-090; am. [Register July 2018 No. 751](#), eff. 8-1-18; EmR2303; emerg. am., eff. 2-3-23; CR 23-072; am. [Register August 2024 No. 824](#), eff. 9-1-24; correction made under s. 35.17, Stats., [Register August 2024 No. 824](#).

Phar 1.02 Definitions. As used in chs. [Phar 1](#) to [19](#):

(1) “Board” means the pharmacy examining board.

Note: The board office is located at 4822 Madison Yards Way, Madison, WI 53705.

(2) “Community pharmacy” means practice in a licensed pharmacy providing pharmaceutical services primarily on an out-patient basis.

(2m) “Department” means the Wisconsin department of safety and professional services.

(3) “DEA” means the drug enforcement administration.

(3m) “Direct supervision” means immediate, whether in person or real time video conferencing where all parties can communicate by simultaneous means of audio, video, or data communications, availability to continually coordinate, direct and inspect in real time the practice of another.

(4) “Institutional pharmacy” means practice in a licensed pharmacy providing pharmaceutical services primarily on an in-patient basis.

(4m) “Long term care facility” has the meaning given in [21 CFR 1300.01](#).

(5) “LTCF” means a long term care facility.

(6) “Managing pharmacist” means a pharmacist designated by the pharmacy owner to have responsibility for and direct control of pharmaceutical operations in a pharmacy.

(6m) “NABP” means the National Association of Boards of Pharmacy.

(7) “NAPLEX” means the North American Pharmacy Licensing Examination.

(8) “Pharmacist” has the meaning given in s. [450.01 \(15\)](#), Stats.

(10) “Pharmacy” means any place of practice licensed by the board under s. [450.06](#) or [450.065](#), Stats., unless otherwise provided for in s. [450.065](#), Stats.

(10m) “Pharmacy graduate” means a graduate of a school of pharmacy approved by the board, who has submitted an application for pharmacist licensure or a qualified applicant awaiting examination for licensure approved by the board.

(11) “Pharmacy owner” means a person or entity to whom a pharmacy license is issued.

(11m) “Pharmacy technician” means a person registered by the board under s. [450.068](#), Stats.

(12) “Practice of pharmacy” has the meaning under s. [450.01 \(16\)](#), Stats.

(13) “PRN” means renew as needed.

(14) “Professional service area” means the area of a pharmacy in which prescriptions are compounded or dispensed, hypodermic needles, syringes, poisons and schedule V controlled substances as listed in s. [961.22](#), Stats., and ch. [CSB 2](#) are available, or where patients are consulted.

(14m) “Remote dispensing site” has the meaning given in s. [450.01 \(21c\)](#), Stats.

(15) “Terminal illness” means an incurable condition caused by injury or illness that reasonable medical judgment finds would cause death.

History: Cr. [Register, January, 1983, No. 325](#), eff. 2-1-83; am. (intro.), renum. (2) to (9) to be (6) to (12) and (14) and am. (8), (10) and (12), cr. (2) to (5) and (13), [Register, August, 1991, No. 428](#), eff. 9-1-91; cr. (4m) and (15), [Register, September, 1994, No. 465](#), eff. 10-1-94; am. (7), (8), (11) and (14), [Register, December, 1998, No. 516](#), eff. 1-1-99; am. (intro.), [Register, March, 2000, No. 531](#), eff. 4-1-00; emerg. cr. (3c), (4c), (4e), and (14m), eff. 1-1-02; correction in (intro.) made under s. 13.93 (2m) (b) 7., Stats., [Register January 2002 No. 553](#); CR 14-023; am. (7) [Register August 2014 No. 704](#), eff. 9-1-14; CR 15-064; am. (10) [Register September 2016 No. 729](#), eff. 10-1-16; CR 16-017; cr. (6m) [Register September 2016 No. 729](#), eff. 10-1-16; correction in (10) made under s. 35.17, Stats., [Register September 2016 No. 729](#); 2017 Wis. Act 18; am. (4m) [Register June 2017 No. 738](#), eff. July 1, 2017; CR 17-090; am. (intro.) [Register July 2018 No. 751](#), eff. 8-1-18; EmR2213; emerg. r. (9), cr. (14m), eff. 11-1-22; CR 23-054; cr. (3m), r. (9), cr. (10m), (14m) [Register August 2024 No. 824](#), eff. 9-1-24; EmR2303; emerg. am. (intro.), cr. (11m), eff. 2-3-23; CR 23-072; am. (intro.), cr. (2m), (11m) [Register August 2024 No. 824](#), eff. 9-1-24.